Acrivon Therapeutics announced progress on ACR-7280, a potential first-in-class oral CDK11 inhibitor showing complete tumor regression in aggressive acute myeloid leukemia (AML) models. Prioritized from multiple candidates using their AI-driven AP3 platform, ACR-7280 demonstrated potent anti-tumor activity and synergy with existing AML treatments like venetoclax. IND-enabling studies are ongoing with plans to submit to the FDA in the first half of 2027, focusing initially on AML treatment both as a single agent and in combination therapies. This advancement highlights Acrivon's innovative drug discovery approach and potential new treatment options for refractory AML.
Acrivon Therapeutics' ACR-7280 progress is notable for readers tracking health innovation. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:03 WIB: out of 150 priced health-sector US stocks, 81 rose and 62 fell. Key movers include RXRX at USD 3.54 with a 1-day change of -1.94% and Pluang order activity of 72% Sell / 28% Buy, ALC at USD 67.41 with a 1-day change of +1.94% and 0% Sell / 100% Buy, and NUVB at USD 4.40 with a 1-day change of -1.79%.
Hershey is preparing to announce its Q3 earnings on October 29, with analysts forecasting earnings per share (EPS) of $2.12, a 63% increase from last year, and revenue of $3.25 billion, up 2.3%. The company has shown strong recent performance, with Q...
3M reported strong Q3 2026 earnings with adjusted EPS of $2.50, beating estimates of $2.38, and GAAP profit rising to $1.37 billion from $834 million a year earlier. Sales reached $6.6 billion, slightly below estimates, but showed 3.3% organic growth...
Alaska Air Group is set to report Q3 2026 earnings with analysts expecting a 66.7% drop in earnings per share to $0.35, despite a 14.5% increase in revenue to $4.31 billion driven by strong travel demand. Passenger revenue is forecast to rise 10.2%, ...
Baba, an applied AI company focused on modernizing Medicare and Medicaid care, has raised $40 million in a Series A funding round led by FirstMark Capital, with participation from CVS Health Ventures and others. The funding will help Baba expand its ...
Richard Campbell-Breeden, a seasoned investment banker with 37 years of experience including 27 years at Goldman Sachs, has joined SEDA Experts LLC as Managing Director. His expertise in mergers and acquisitions, corporate finance, and governance wil...
